MedPath

Comparison of PEEP in Acute Decompensated Heart Failure

Not Applicable
Conditions
Heart Decompensation
Mechanical Ventilation Pressure High
Registration Number
NCT04853563
Lead Sponsor
Asan Medical Center
Brief Summary

Little is known about optimal level of positive end-expiratory pressure (PEEP) in patiens who recieved invasive mechanical ventilation for acute decompensated heart failure. We therefore sought to compare clinical outcome according to low versus high PEEP.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
120
Inclusion Criteria
  1. Subject who was diagnosed with congestive heart failure and objective evidence of pulmonary congestion (pulmonary edema on simple chest radiography or positive B-line on lung ultrasonography AND elevated B-type natriuretic peptide or N-terminal pro-brain natriuretic peptide level) as a reason for invasive mechanical ventilation
  2. Age over 19 years old
  3. Subject who agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the clinical site.
Exclusion Criteria
  1. Subject who are on mechanical circulatory support (ECMO, intra-aortic balloon pump, VAD) at the time of randomization
  2. Subject who has cardiac abnormality that requires emergent or urgent percutaneous or surgical valvular procedure
  3. Subject who are on vasoactive or inotropic agents at least moderate dose defined as vasoactive-inotropic score >10
  4. Isolated preload-dependent cardiac dysfunction (isolated right ventricular failure, right ventricular infarction, constrictive pericarditis, cardiac tamponade, severe pulmonary hypertension without LV dysfunction)
  5. Predominant right ventricular failure defined as following; clinical evidence of right ventricular failure by attending physician's discretion including hepatojugular reflux, Kussmaul sign, cardiac liver cirrhosis, hepato/splenomegaly, acites, thronmbocytopenia, etc.
  6. Subject who are not on mechanical ventilation before open heart surgery
  7. Subject who received unwitness cardiopulmonary rescucitation (CPR) or witness CPR lasting more than 30 minutes
  8. Subject who was already diagnosed or is suspected to have hypertophic cardiomyopathy with significant left ventricular outflow tract (LVOT) obstruction
  9. Subject with intracranial hemorrahge or ischemic stroke at the time of randomization
  10. Subject with irreversible neurologic damage or irreversible hepatic failure
  11. Invasive mechanical ventilation lasting more than 24 hours preceding endotracheal intubation
  12. Subject with underlying chronic obstructive pulmonary disease (GOLD classification III or IV) or restrictive pulmonary disease (e.g. interstitial lung disease)
  13. Subject with impaired consciousness that can not perform self coughing and need suction to maintain adequate airway patency
  14. Pregnant and/or lactating women
  15. Subject with life expectancy less than a year
  16. Subject who is not suitable to enrollment by investigator's discretion

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Ventilator-free day at 28-dayup to 28-day

Starting at the day of randomization, and the days on non-invasive ventilation do not count. Successful extubation is defined as at least 24 hours wihtout reintubation independent of invasive assisted ventilation in survivor. Non-survivor within 28 days: ventilator-free day counted as 0, ventilator-free day among only survivor at 28-day will be counted for primary endpoint.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Min Seok Kim, PhD
Contact
02-3010-3948
guess124@gmail.com
© Copyright 2025. All Rights Reserved by MedPath